Sarepta (NASDAQ: SRPT) is recently up $4.40 to $27.41 in the premarket after announcing that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). June weekly call option implied volatility is at 237, June is at 314, July is at 261; compared to its 52-week range of 65 to 400